Soligenix COVID-19 Vaccine, CiVax™, Boosts Neutralizing Activity against SARS-CoV-2, including Delta and Omicron

• CiVax™ booster vaccine administered seven months after primary vaccination with COVID-19 adenovirus vaccine shows rapid enhancement of neutralizing antibody responses in non-human primates
• Neutralizing antibodies against Delta and original strain increased by up to 27-fold within one week and up to 243-fold within three weeks
• Omicron neutralizing antibody levels were undetectable prior to booster vaccination, and attained presumed protective levels within one week of vaccination

Excerpt from the Press Release:

PRINCETON, N.J., March 17, 2022 /PRNewswire/ — Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the results of a booster vaccination study using CiVax™ (heat stable COVID-19 subunit vaccine program) in non-human primates (NHPs) demonstrating rapid enhancement of neutralizing antibody responses to SARS-CoV-2, including against Delta and Omicron variants. The NHPs had been double vaccinated with an adenovirus vaccine for COVID-19 seven months previously. Prior to administration of the booster vaccine, neutralizing antibody levels against the original and Delta strains of SARS-CoV-2 were low, but detectable, and were undetectable for the Omicron strain. Within one week of receiving booster, neutralizing antibody levels increased as much as 27-fold against the original and Delta strains. By three weeks this increased up to 243-fold. Protective neutralizing antibody levels were also rapidly raised against Omicron by one-week post-vaccination. These results are consistent with the broad-spectrum activity observed to date with CiVax™ on primary vaccination, as described in an article recently published by ACS Infectious Diseases.

These most recent results are part of the ongoing collaboration with Axel Lehrer, PhD, Associate Professor at the Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine (JABSOM), University of Hawaiʻi at Mānoa (UHM). CiVax™ development continues under a non-dilutive $1.5M Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) awarded to Soligenix in December 2020.

Click the button below to read the entire Press Release:

Continue Reading The Press Release